Prognostic value of expression of survivin and ki67 in head and neck squamous cell carcinoma treated by chemoradiotherapy

Life Science Journal

Volumn 8, Issue 2, 2011, Pages 724-733

  Gizawy, Samy M Al ^a   Essa, Hoda H ^a   Refaiy, Abeer M ^a   Elosaily, Gehan M ^a   Ahmed, H E ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Prognostic Value Of Expression Of Survivin And Ki67 In Head And Neck Squamous Cell Carcinoma Treated By Chemoradiotherapy

Indexed keywords

EID: 79957863772     PISSN: 10978135     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Adelstein DJ, Li Y, Adams GL, Wagner HJr, Kish JA, Ensley JF, Schuller DE, Forastiere AA. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-8.
2. Calais G, Alfonsi M, Bardet E, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Oudinot P, Bertrand P. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. JNatl Cancer Inst 1999;91: 2081-6.
3. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, Bergerot P, Rhein B, Tortochaux J, Calais G. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol 2004; 22: 69-76.
4. Wendt TG, Grabenbauer GG, Rodel CM, Thiel HJ, Aydin H, Rohloff R, Wustrow TP, Iro H, Popella C, Schalhorn A. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998; 16: 1318-24.
5. van den Broek GB, Wildeman M, Rasch CR, Armstrong N, et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer. 2009 Jun 1;124(11): 2643-50.
6. Bradford CR. Predictive factors in head and neck cancer. Hematol Oncol Clin North Am. 1999;13(4): 777-785.
7. Bentzen SM, Atasoy BM, Daley FM; et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol. 2005;23(24): 5560-5567.
8. Bhavna Kumar, MSC; Kitrina G. Cordell, DDS; Nisha D'Silva, et al. Expression of p53 and Bcl-xL as Predictive Markers for Larynx Preservation in advanced Laryngeal CancerArch Otolaryngol Head Neck Surg. 2008;134(4): 363-369.
9. Karsai S, Abel U, Roesch-Ely M; et al. Comparison of p16INK4a expression with p53 alterations in head and neck cancer by tissue microarray analysis. J Pathol. 2007;211(3): 314-322.
10. Altieri DC: Targeted therapy by disabling crossroad signaling networks: the survivin paradigm. Molecular cancer therapeutics 2006, 5(3): 478-482.
11. Yamamoto T, Tanigawa N: The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001, 34(4): 207-212.
12. Nordgard S, Franzen G, Boysen M, Halvorsen TB: Ki-67 as a prognostic marker in adenoid cystic carcinoma assessed with the monoclonal antibody MIB1 in paraffin sections. Laryngoscope 1997, 107(4): 531-536.
13. AJCC Cancer Staging Manual, Sixth Edition 2002 published by Springer-Verlag New York, www.springeronline.com.
14. Taubert H, Heidenreich C, Holzhausen HJ, Schulz A, et al. Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients. BMC Cancer. 2010 Feb 24;10: 65.
15. Khan Z, Tiwari RP, Mulherkar R, Sah NK, Prasad GB, Shrivastava BR, Bisen PS: Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. Head Neck 2009, 31(8): 1039-1048.
16. Marioni G, Ottaviano G, Marchese-Ragona R, Giacomelli L, Bertolin A, Zanon D, Marino F, Staffieri A: High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma. Acta Otolaryngol 2006, 126(2): 197-203.
17. Qi G, Kudo Y, Ando T, Tsunematsu T, Shimizu N, Siriwardena SB, Yoshida M, etal. Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol. 2010 Apr;46(4): 263-70
18. Engels K, Knauer SK, Metzler D, Simf C, Struschka O, Bier C, et al., Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol. 2007 Apr;211(5): 532-40.
19. Li F, Yang J, Ramnath N, Javle MM, Tan D: Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 2005, 114(4): 509-512.
20. Preuss SF, Weinell A, Molitor M, Semrau R, Stenner M, Drebber U, Wedemeyer I, Hoffmann TK, Guntinas-Lichius O, Klussmann JP: Survivin and epidermal growth factor receptor expression in surgically treated oropharyngeal squamous cell carcinoma. Head Neck 2008, 30(10): 1318-1324.
21. Freier K, Pungs S, Sticht C, Flechtenmacher C, Lichter P, Joos S, Hofele C: High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer 2007, 120(4): 942-946.
22. Kennedy SM, O'Driscoll L, Purcell R, Fitz-Simons N, McDermott EW, Hill AD, O'Higgins NJ, Parkinson M, Linehan R, Clynes M. Prognostic importance of survivin in breast cancer. Br J Cancer 2003;88: 1077-83.
23. Ponnelle T, Chapusot C, Martin L, Bouvier AM, Plenchette S, Faivre J, Solary E, Piard F. Cellular localisation of survivin: impact on the prognosis in colorectal cancer. J Cancer Res Clin Oncol 2005;131: 504-10.
24. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003;29: 379-82.
25. Lehner R, Lucia MS, Jarboe EA, Orlicky D, Shroyer AL, McGregor JA, Shroyer KR. Immunohistochemical localization of the IAP protein survivin in bladder mucosa and transitional cell carcinoma. Appl Immunohistochem Molecul Morphol 2002;10: 134-8.
26. Lin CY, Hung HC, Kuo RC, Chiang CP, Kuo MY. Survivin expression predicts poorer prognosis in patients with areca quid chewingrelated oral squamous cell carcinoma in Taiwan. Oral Oncol 2005;41: 645-54.
27. Lo Muzio L, Farina A, Rubini C, Pezzetti F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo A, Carinci F. Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett. 2005;225: 27-33.
28. Ko YH, Roh SY, Won HS, Jeon EK, Hong SH, Lee MA, Kang JH, Hong YS, Kim MS, Jung CK. Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol. 2010 Oct 30;2: 30.
29. Sarela AI, Macadam RC, Farmery SM, Markham AF, Guillou PJ: Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46(5): 645-650.
30. Span PN, Sweep FC, Wiegerinck ET, Tjan-Heijnen VC, Manders P, Beex LV, de Kok JB: Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004, 50(11): 1986-1993.
31. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B: Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer 2005, 103(8): 1685-1692.
32. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, Heine B, Stein H, Hopfner M, Germer CT, Scherubl H: Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br j Cancer 2003, 13;88(1): 115-119.
33. Warnecke-Eberz U, Hokita S, Xi H, Higashi H, Baldus SE, Metzger R, Brabender J, Bollschweiler E, Mueller RP, Dienes HP, Hoelscher AH, Schneider PM. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 2005;13: 1241-6.
34. Beardsmore DM, Verbeke CS, Davies CL, Guillou PJ, Clark GW. Apoptotic and proliferative indexes in esophageal cancer: predictors of response to neoadjuvant therapy [corrected]. J Gastrointest Surg 2003; 7: 77-86; discussion 86-7.
35. Ashraf MJ, Maghbul M, Azarpira N, Khademi B. Expression of Ki67 and P53 in primary squamous cell carcinoma of the larynx. Indian J Pathol Microbiol. 2010 Oct-Dec;53(4): 661-5.
36. Jaworska M, Kołosza Z, Liszka J, Nikiel B, Golen M, Lange D, Scierski W, Namysłowski G. Prognostic molecular markers in oral and lip squamous cell carcinoma-evaluation of expression and its significance. Otolaryngol Pol. 2008;62(2): 175-81.